PT1557414E - Compostos de isoquinolina e sua utilização medicinal - Google Patents
Compostos de isoquinolina e sua utilização medicinal Download PDFInfo
- Publication number
- PT1557414E PT1557414E PT03748659T PT03748659T PT1557414E PT 1557414 E PT1557414 E PT 1557414E PT 03748659 T PT03748659 T PT 03748659T PT 03748659 T PT03748659 T PT 03748659T PT 1557414 E PT1557414 E PT 1557414E
- Authority
- PT
- Portugal
- Prior art keywords
- isoquinolin
- methyl
- ethyl
- hydroxyl
- formula
- Prior art date
Links
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title description 2
- -1 isoquinoline compound Chemical class 0.000 claims abstract description 187
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 78
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 150000003839 salts Chemical class 0.000 claims abstract description 65
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000012453 solvate Substances 0.000 claims abstract description 56
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 38
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 35
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims abstract description 25
- 238000011321 prophylaxis Methods 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 230000001154 acute effect Effects 0.000 claims abstract description 14
- 206010060860 Neurological symptom Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims abstract description 8
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 87
- 229910052757 nitrogen Inorganic materials 0.000 claims description 75
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 56
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 51
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 50
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 37
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 33
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 32
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 125000002252 acyl group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000004442 acylamino group Chemical group 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 18
- XWECNAFOEYMONG-UHFFFAOYSA-N 3-[1-(2-hydroxyethyl)pyrrolidin-3-yl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2C1CCN(CCO)C1 XWECNAFOEYMONG-UHFFFAOYSA-N 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- LIENERAPGZENEN-CYBMUJFWSA-N 3-[2-[(3r)-3-hydroxypyrrolidin-1-yl]ethyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCN1CC[C@@H](O)C1 LIENERAPGZENEN-CYBMUJFWSA-N 0.000 claims description 17
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- QXWVLYFKOBMHAX-UHFFFAOYSA-N 3-[1-(2-hydroxyethyl)piperidin-4-yl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2C1CCN(CCO)CC1 QXWVLYFKOBMHAX-UHFFFAOYSA-N 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- JIODGUURCXVIDC-CQSZACIVSA-N 3-[2-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCN1CCC[C@@H]1CO JIODGUURCXVIDC-CQSZACIVSA-N 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims description 11
- JQKXZSNEWNLBFY-UHFFFAOYSA-N 3-[1-(3-hydroxy-2,2-dimethylpropyl)piperidin-4-yl]-2h-isoquinolin-1-one Chemical compound C1CN(CC(C)(CO)C)CCC1C1=CC2=CC=CC=C2C(=O)N1 JQKXZSNEWNLBFY-UHFFFAOYSA-N 0.000 claims description 10
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 10
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims description 10
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 10
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 10
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- ZUWCWDVCTQUWCN-UHFFFAOYSA-N 3-[1-(2-hydroxyethyl)piperidin-4-yl]-2h-isoquinolin-1-one Chemical compound C1CN(CCO)CCC1C1=CC2=CC=CC=C2C(=O)N1 ZUWCWDVCTQUWCN-UHFFFAOYSA-N 0.000 claims description 9
- LIENERAPGZENEN-UHFFFAOYSA-N 3-[2-(3-hydroxypyrrolidin-1-yl)ethyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCN1CCC(O)C1 LIENERAPGZENEN-UHFFFAOYSA-N 0.000 claims description 9
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 9
- NAPGQYRCBAXPOF-UHFFFAOYSA-N 3-[2-(4-hydroxypiperidin-1-yl)ethyl]-2h-isoquinolin-1-one Chemical compound C1CC(O)CCN1CCC1=CC2=CC=CC=C2C(=O)N1 NAPGQYRCBAXPOF-UHFFFAOYSA-N 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- TXUFILTZRPBNKF-UHFFFAOYSA-N 3-[2-(3-hydroxypiperidin-1-yl)ethyl]-2h-isoquinolin-1-one Chemical compound C1C(O)CCCN1CCC1=CC2=CC=CC=C2C(=O)N1 TXUFILTZRPBNKF-UHFFFAOYSA-N 0.000 claims description 7
- OONSUNORLYNRAU-UHFFFAOYSA-N 3-[2-(3-hydroxypiperidin-1-yl)ethyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCN1CCCC(O)C1 OONSUNORLYNRAU-UHFFFAOYSA-N 0.000 claims description 7
- YYYVYXMNBZYNRI-UHFFFAOYSA-N 3-[2-(3-hydroxypyrrolidin-1-yl)ethyl]-2h-isoquinolin-1-one Chemical compound C1C(O)CCN1CCC1=CC2=CC=CC=C2C(=O)N1 YYYVYXMNBZYNRI-UHFFFAOYSA-N 0.000 claims description 7
- IEIDXMXYLCNJOS-BTQNPOSSSA-N 3-[2-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl]-5-methylisochromen-1-one;hydrochloride Chemical compound Cl.CC1=CC=CC(C(O2)=O)=C1C=C2CCN1CCC[C@@H]1CO IEIDXMXYLCNJOS-BTQNPOSSSA-N 0.000 claims description 7
- WGMHTWZGWRXPBC-UHFFFAOYSA-N 3-[2-[2-(hydroxymethyl)piperidin-1-yl]ethyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCN1CCCCC1CO WGMHTWZGWRXPBC-UHFFFAOYSA-N 0.000 claims description 7
- GWFZPZHPMDALSO-OAHLLOKOSA-N 3-[3-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]propyl]-2h-isoquinolin-1-one Chemical compound OC[C@H]1CCCN1CCCC1=CC2=CC=CC=C2C(=O)N1 GWFZPZHPMDALSO-OAHLLOKOSA-N 0.000 claims description 7
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- NARVIWMVBMUEOG-UHFFFAOYSA-N 2-Hydroxy-propylene Natural products CC(O)=C NARVIWMVBMUEOG-UHFFFAOYSA-N 0.000 claims description 6
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 6
- 239000005977 Ethylene Substances 0.000 claims description 6
- GROMINZTXHTDBD-UHFFFAOYSA-N 3-[1-(2-hydroxypropyl)piperidin-4-yl]-5-methyl-2h-isoquinolin-1-one Chemical compound C1CN(CC(O)C)CCC1C1=CC2=C(C)C=CC=C2C(=O)N1 GROMINZTXHTDBD-UHFFFAOYSA-N 0.000 claims description 5
- OMAQKFOMSJZAEC-UHFFFAOYSA-N 3-[1-(4-hydroxybutyl)piperidin-4-yl]-2h-isoquinolin-1-one Chemical compound C1CN(CCCCO)CCC1C1=CC2=CC=CC=C2C(=O)N1 OMAQKFOMSJZAEC-UHFFFAOYSA-N 0.000 claims description 5
- LIENERAPGZENEN-ZDUSSCGKSA-N 3-[2-[(3s)-3-hydroxypyrrolidin-1-yl]ethyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCN1CC[C@H](O)C1 LIENERAPGZENEN-ZDUSSCGKSA-N 0.000 claims description 4
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 claims description 4
- 208000013403 hyperactivity Diseases 0.000 claims description 4
- CLUVXURRWPESGP-UHFFFAOYSA-N 3-[1-(2-hydroxypropyl)piperidin-4-yl]-2h-isoquinolin-1-one Chemical compound C1CN(CC(O)C)CCC1C1=CC2=CC=CC=C2C(=O)N1 CLUVXURRWPESGP-UHFFFAOYSA-N 0.000 claims description 3
- AWNXRFGEQAQROI-UHFFFAOYSA-N 3-[1-(3-hydroxypropyl)piperidin-4-yl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2C1CCN(CCCO)CC1 AWNXRFGEQAQROI-UHFFFAOYSA-N 0.000 claims description 3
- WJBFPOCCDVAXQR-OAHLLOKOSA-N 3-[3-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]propyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCCN1CCC[C@@H]1CO WJBFPOCCDVAXQR-OAHLLOKOSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- OKVBEBCBQZYBLN-AWEZNQCLSA-N 3-[2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl]-2h-isoquinolin-1-one Chemical compound OC[C@@H]1CCCN1CCC1=CC2=CC=CC=C2C(=O)N1 OKVBEBCBQZYBLN-AWEZNQCLSA-N 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 4
- CONQPYQMWOUPAB-UHFFFAOYSA-N 3-[3-(3-hydroxypyrrolidin-1-yl)propyl]-2h-isoquinolin-1-one Chemical compound C1C(O)CCN1CCCC1=CC2=CC=CC=C2C(=O)N1 CONQPYQMWOUPAB-UHFFFAOYSA-N 0.000 claims 2
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 claims 2
- PLRXAFVBCHEMGD-UHFFFAOYSA-N 3-piperidin-1-ylpropan-1-ol Chemical compound OCCCN1CCCCC1 PLRXAFVBCHEMGD-UHFFFAOYSA-N 0.000 claims 1
- TXKYEKYEUFNENF-QXMSRBDHSA-N CON(C)C(=O)CCN1CCC[C@@H]1CO.CC1=CC=CC(C(O2)=O)=C1C=C2CCN1CC[C@@H](O)C1 Chemical compound CON(C)C(=O)CCN1CCC[C@@H]1CO.CC1=CC=CC(C(O2)=O)=C1C=C2CCN1CC[C@@H](O)C1 TXKYEKYEUFNENF-QXMSRBDHSA-N 0.000 claims 1
- LZNLYGKKIITCMD-CMSMCRNYSA-N N,N-diethyl-2-[4-[(3R)-3-hydroxypyrrolidin-1-yl]-2-oxobutyl]-3-methylbenzamide 3-[(3R)-3-hydroxypyrrolidin-1-yl]-N-methoxy-N-methylpropanamide Chemical compound CON(C)C(=O)CCN1CC[C@@H](O)C1.CCN(CC)C(=O)C1=CC=CC(C)=C1CC(=O)CCN1C[C@H](O)CC1 LZNLYGKKIITCMD-CMSMCRNYSA-N 0.000 claims 1
- IZNXFWOKWZUNHD-UHFFFAOYSA-N OC(CN1CCC(CC1)C=1NCC2=CC=CC=C2C1)C Chemical compound OC(CN1CCC(CC1)C=1NCC2=CC=CC=C2C1)C IZNXFWOKWZUNHD-UHFFFAOYSA-N 0.000 claims 1
- MJKCGMAIRPRTTA-GFJIOCRJSA-N OC[C@@H]1N(CCC1)CCC=1OC(=O)C2=CC=CC(=C2C1)C.C(C)N(C(C1=C(C(=CC=C1)C)CC(CCN1[C@H](CCC1)CO)=O)=O)CC Chemical compound OC[C@@H]1N(CCC1)CCC=1OC(=O)C2=CC=CC(=C2C1)C.C(C)N(C(C1=C(C(=CC=C1)C)CC(CCN1[C@H](CCC1)CO)=O)=O)CC MJKCGMAIRPRTTA-GFJIOCRJSA-N 0.000 claims 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 230000000069 prophylactic effect Effects 0.000 abstract description 3
- 229940123066 Polymerase inhibitor Drugs 0.000 abstract 1
- 230000035874 hyperreactivity Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 57
- 239000000203 mixture Substances 0.000 description 47
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 28
- 239000000047 product Substances 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 239000010410 layer Substances 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 17
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 12
- SMVYLWURFNYXTP-UHFFFAOYSA-N n,n-diethyl-2,3-dimethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1C SMVYLWURFNYXTP-UHFFFAOYSA-N 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- KJFNIMLMIUNQSJ-UHFFFAOYSA-N n,n,2,3-tetramethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(C)=C1C KJFNIMLMIUNQSJ-UHFFFAOYSA-N 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- CLEWWQJPZHSJCB-UHFFFAOYSA-N 3-(1-benzylpyrrolidin-3-yl)-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2C(C1)CCN1CC1=CC=CC=C1 CLEWWQJPZHSJCB-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- LDTCNXZQTFXXQO-UHFFFAOYSA-N 3-[3-(3-hydroxypyrrolidin-1-yl)propyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCCN1CCC(O)C1 LDTCNXZQTFXXQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- KUYQDJOFVBGZID-UHFFFAOYSA-N n,n-diethyl-2-methylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=CC=C1C KUYQDJOFVBGZID-UHFFFAOYSA-N 0.000 description 6
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 5
- NMZMRXABGQQSHZ-UHFFFAOYSA-N 3-(2-hydroxy-3-pyrrolidin-1-ylpropyl)-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CC(O)CN1CCCC1 NMZMRXABGQQSHZ-UHFFFAOYSA-N 0.000 description 5
- LLAZEWFHCZQXTJ-MRVPVSSYSA-N 3-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]propanenitrile Chemical compound OC[C@H]1CCCN1CCC#N LLAZEWFHCZQXTJ-MRVPVSSYSA-N 0.000 description 5
- JFTWBVDEGGPRDG-CYBMUJFWSA-N 3-[2-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl]-5-methylisochromen-1-one Chemical compound CC1=CC=CC(C(O2)=O)=C1C=C2CCN1CCC[C@@H]1CO JFTWBVDEGGPRDG-CYBMUJFWSA-N 0.000 description 5
- BYSNLBSAOFVXIV-UHFFFAOYSA-N 3-piperidin-4-yl-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C=1C2=CC=CC=C2C(=O)NC=1C1CCNCC1 BYSNLBSAOFVXIV-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- ZEIHMQRVINLNDA-UHFFFAOYSA-N 3-(2-hydroxy-3-pyrrolidin-1-ylpropyl)-2h-isoquinolin-1-one Chemical compound C=1C2=CC=CC=C2C(=O)NC=1CC(O)CN1CCCC1 ZEIHMQRVINLNDA-UHFFFAOYSA-N 0.000 description 4
- MRLSDLGZLJSOOD-MRVPVSSYSA-N 3-[(3r)-3-hydroxypyrrolidin-1-yl]-n-methoxy-n-methylpropanamide Chemical compound CON(C)C(=O)CCN1CC[C@@H](O)C1 MRLSDLGZLJSOOD-MRVPVSSYSA-N 0.000 description 4
- ANMZDJQCBZIDLO-UHFFFAOYSA-N 3-[1-(3-hydroxypropyl)piperidin-4-yl]-2h-isoquinolin-1-one Chemical compound C1CN(CCCO)CCC1C1=CC2=CC=CC=C2C(=O)N1 ANMZDJQCBZIDLO-UHFFFAOYSA-N 0.000 description 4
- XHKCXYIZKKVNBV-UHFFFAOYSA-N 3-[2-(hydroxymethyl)-1-methylpiperidin-4-yl]-2h-isoquinolin-1-one Chemical compound C1C(CO)N(C)CCC1C1=CC2=CC=CC=C2C(=O)N1 XHKCXYIZKKVNBV-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 4
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- 229940043279 diisopropylamine Drugs 0.000 description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 210000003657 middle cerebral artery Anatomy 0.000 description 4
- OGZWURPKXPEILY-QGZVFWFLSA-N n,n-diethyl-2-[4-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]-2-oxobutyl]-3-methylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1CC(=O)CCN1[C@@H](CO)CCC1 OGZWURPKXPEILY-QGZVFWFLSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- MOANZLCNTGXBDH-SECBINFHSA-N 3-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]-n-methoxy-n-methylpropanamide Chemical compound CON(C)C(=O)CCN1CCC[C@@H]1CO MOANZLCNTGXBDH-SECBINFHSA-N 0.000 description 3
- WVOXJBSAWSCZLL-SSDOTTSWSA-N 3-[(3r)-3-hydroxypyrrolidin-1-yl]propanenitrile Chemical compound O[C@@H]1CCN(CCC#N)C1 WVOXJBSAWSCZLL-SSDOTTSWSA-N 0.000 description 3
- APMCLHCWFIDCDW-UHFFFAOYSA-N 3-[1-(2-hydroxyethyl)pyrrolidin-3-yl]-2h-isoquinolin-1-one Chemical compound C1N(CCO)CCC1C1=CC2=CC=CC=C2C(=O)N1 APMCLHCWFIDCDW-UHFFFAOYSA-N 0.000 description 3
- NLMTUCSKIOCANV-GFCCVEGCSA-N 3-[2-[(3r)-3-hydroxypyrrolidin-1-yl]ethyl]-5-methylisochromen-1-one Chemical compound CC1=CC=CC(C(O2)=O)=C1C=C2CCN1CC[C@@H](O)C1 NLMTUCSKIOCANV-GFCCVEGCSA-N 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000012661 PARP inhibitor Substances 0.000 description 3
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 235000012501 ammonium carbonate Nutrition 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- QDVKQOHTQTXGQG-QGZVFWFLSA-N n,n-diethyl-2-[4-[(3r)-3-hydroxypyrrolidin-1-yl]-2-oxobutyl]-3-methylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1CC(=O)CCN1C[C@H](O)CC1 QDVKQOHTQTXGQG-QGZVFWFLSA-N 0.000 description 3
- IAAVEAHABZTBNK-UHFFFAOYSA-N n-methoxy-n-methylprop-2-enamide Chemical compound CON(C)C(=O)C=C IAAVEAHABZTBNK-UHFFFAOYSA-N 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003246 quinazolines Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- NMKZYSKALMMFRX-UHFFFAOYSA-N 3-(3-hydroxypiperidin-1-yl)propanenitrile Chemical compound OC1CCCN(CCC#N)C1 NMKZYSKALMMFRX-UHFFFAOYSA-N 0.000 description 2
- WVOXJBSAWSCZLL-UHFFFAOYSA-N 3-(3-hydroxypyrrolidin-1-yl)propanenitrile Chemical compound OC1CCN(CCC#N)C1 WVOXJBSAWSCZLL-UHFFFAOYSA-N 0.000 description 2
- JTBAFYUTGVVDSC-UHFFFAOYSA-N 3-(4-hydroxypiperidin-1-yl)propanenitrile Chemical compound OC1CCN(CCC#N)CC1 JTBAFYUTGVVDSC-UHFFFAOYSA-N 0.000 description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- PYLOSKJCVWOKQB-UHFFFAOYSA-N 3-[1-(4-hydroxybutyl)piperidin-4-yl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2C1CCN(CCCCO)CC1 PYLOSKJCVWOKQB-UHFFFAOYSA-N 0.000 description 2
- TYVZAIKBKZFMOC-UHFFFAOYSA-N 3-[2-(hydroxymethyl)piperidin-1-yl]propanenitrile Chemical compound OCC1CCCCN1CCC#N TYVZAIKBKZFMOC-UHFFFAOYSA-N 0.000 description 2
- DPLDVAMURIZEAX-UHFFFAOYSA-N 3-[2-(hydroxymethyl)piperidin-4-yl]-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C1CNC(CO)CC1C1=CC2=CC=CC=C2C(=O)N1 DPLDVAMURIZEAX-UHFFFAOYSA-N 0.000 description 2
- OONSUNORLYNRAU-CQSZACIVSA-N 3-[2-[(3r)-3-hydroxypiperidin-1-yl]ethyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCN1CCC[C@@H](O)C1 OONSUNORLYNRAU-CQSZACIVSA-N 0.000 description 2
- RRYANHCYUXNQAO-UHFFFAOYSA-N 3-[2-[2-(hydroxymethyl)piperidin-1-yl]ethyl]-2h-isoquinolin-1-one Chemical compound OCC1CCCCN1CCC1=CC2=CC=CC=C2C(=O)N1 RRYANHCYUXNQAO-UHFFFAOYSA-N 0.000 description 2
- AMJAYWLGVUVHFT-UHFFFAOYSA-N 3-hydroxy-4-pyrrolidin-1-ylbutanenitrile Chemical compound N#CCC(O)CN1CCCC1 AMJAYWLGVUVHFT-UHFFFAOYSA-N 0.000 description 2
- ALIPVUXYTJLUKJ-UHFFFAOYSA-N 4-(3-hydroxypyrrolidin-1-yl)butanenitrile Chemical compound OC1CCN(CCCC#N)C1 ALIPVUXYTJLUKJ-UHFFFAOYSA-N 0.000 description 2
- SIJLYRDVTMMSIP-UHFFFAOYSA-N 4-Bromo-1-butanol Chemical compound OCCCCBr SIJLYRDVTMMSIP-UHFFFAOYSA-N 0.000 description 2
- LFPKFWAKANIVJZ-SECBINFHSA-N 4-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]butanenitrile Chemical compound OC[C@H]1CCCN1CCCC#N LFPKFWAKANIVJZ-SECBINFHSA-N 0.000 description 2
- RYOZAPMJJSDSEH-UHFFFAOYSA-N 5-methyl-3-piperidin-4-yl-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.CC1=CC=CC(C(N2)=O)=C1C=C2C1CCNCC1 RYOZAPMJJSDSEH-UHFFFAOYSA-N 0.000 description 2
- WESKABPAQNGQTH-UHFFFAOYSA-N 5-methyl-3-pyrrolidin-3-yl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2C1CCNC1 WESKABPAQNGQTH-UHFFFAOYSA-N 0.000 description 2
- POZYCVGJUOHKPX-UHFFFAOYSA-N 5-methyl-3-pyrrolidin-3-yl-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.CC1=CC=CC(C(N2)=O)=C1C=C2C1CCNC1 POZYCVGJUOHKPX-UHFFFAOYSA-N 0.000 description 2
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- AHNJTQYTRPXLLG-UHFFFAOYSA-N lithium;diethylazanide Chemical compound [Li+].CC[N-]CC AHNJTQYTRPXLLG-UHFFFAOYSA-N 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- QPMSJEFZULFYTB-PGMHMLKASA-N (3r)-pyrrolidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCNC1 QPMSJEFZULFYTB-PGMHMLKASA-N 0.000 description 1
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- YZHKLNCWNQOYHN-UHFFFAOYSA-N 1,2-dihydroisoquinoline;hydrochloride Chemical compound Cl.C1=CC=C2CNC=CC2=C1 YZHKLNCWNQOYHN-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RYCQUUNQHVAFSM-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carbonitrile Chemical compound C1C(C#N)CCN1CC1=CC=CC=C1 RYCQUUNQHVAFSM-UHFFFAOYSA-N 0.000 description 1
- WEGOLYBUWCMMMY-UHFFFAOYSA-N 1-bromo-2-propanol Chemical compound CC(O)CBr WEGOLYBUWCMMMY-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NMKZYSKALMMFRX-MRVPVSSYSA-N 3-[(3r)-3-hydroxypiperidin-1-yl]propanenitrile Chemical compound O[C@@H]1CCCN(CCC#N)C1 NMKZYSKALMMFRX-MRVPVSSYSA-N 0.000 description 1
- WVOXJBSAWSCZLL-ZETCQYMHSA-N 3-[(3s)-3-hydroxypyrrolidin-1-yl]propanenitrile Chemical compound O[C@H]1CCN(CCC#N)C1 WVOXJBSAWSCZLL-ZETCQYMHSA-N 0.000 description 1
- BUTMCNPFYGBNLV-UHFFFAOYSA-N 3-[1-(3-hydroxypropyl)pyrrolidin-3-yl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2C1CCN(CCCO)C1 BUTMCNPFYGBNLV-UHFFFAOYSA-N 0.000 description 1
- OKVBEBCBQZYBLN-CQSZACIVSA-N 3-[2-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl]-2h-isoquinolin-1-one Chemical compound OC[C@H]1CCCN1CCC1=CC2=CC=CC=C2C(=O)N1 OKVBEBCBQZYBLN-CQSZACIVSA-N 0.000 description 1
- JIODGUURCXVIDC-AWEZNQCLSA-N 3-[2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCN1CCC[C@H]1CO JIODGUURCXVIDC-AWEZNQCLSA-N 0.000 description 1
- GWFZPZHPMDALSO-HNNXBMFYSA-N 3-[3-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]propyl]-2h-isoquinolin-1-one Chemical compound OC[C@@H]1CCCN1CCCC1=CC2=CC=CC=C2C(=O)N1 GWFZPZHPMDALSO-HNNXBMFYSA-N 0.000 description 1
- WJBFPOCCDVAXQR-HNNXBMFYSA-N 3-[3-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]propyl]-5-methyl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2CCCN1CCC[C@H]1CO WJBFPOCCDVAXQR-HNNXBMFYSA-N 0.000 description 1
- KQOQXYPZBYTICM-UHFFFAOYSA-N 3-bromo-2,2-dimethylpropan-1-ol Chemical compound OCC(C)(C)CBr KQOQXYPZBYTICM-UHFFFAOYSA-N 0.000 description 1
- YFMKNZIGHOSFKE-UHFFFAOYSA-N 3-bromopropan-1-ol hydrochloride Chemical compound Cl.OCCCBr YFMKNZIGHOSFKE-UHFFFAOYSA-N 0.000 description 1
- ZHFFBGSPIZXTQB-UHFFFAOYSA-N 3-pyrrolidin-3-yl-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C=1C2=CC=CC=C2C(=O)NC=1C1CCNC1 ZHFFBGSPIZXTQB-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- NVSLWVXNTNKTGU-UHFFFAOYSA-N 5-methyl-3-piperidin-4-yl-2h-isoquinolin-1-one Chemical compound CC1=CC=CC(C(N2)=O)=C1C=C2C1CCNCC1 NVSLWVXNTNKTGU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- PYHZKAVSQPNGCH-UHFFFAOYSA-N Cl.BrCC(C)O Chemical compound Cl.BrCC(C)O PYHZKAVSQPNGCH-UHFFFAOYSA-N 0.000 description 1
- HVVNJUAVDAZWCB-RXMQYKEDSA-N D-prolinol Chemical compound OC[C@H]1CCCN1 HVVNJUAVDAZWCB-RXMQYKEDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- PGIOMNLZJUQZCU-MRXNPFEDSA-N [(2R)-1-[2-(5-methyl-1,2-dihydroisoquinolin-3-yl)ethyl]pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1N(CCC1)CCC=1NCC2=CC=CC(=C2C=1)C PGIOMNLZJUQZCU-MRXNPFEDSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 125000006630 butoxycarbonylamino group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 210000004491 foramen ovale Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical class C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- PRAYXGYYVXRDDW-UHFFFAOYSA-N piperidin-2-ylmethanol Chemical compound OCC1CCCCN1 PRAYXGYYVXRDDW-UHFFFAOYSA-N 0.000 description 1
- 230000005731 poly ADP ribosylation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GIPYSZWEUUHGRI-UHFFFAOYSA-N tert-butyl 4-cyano-2-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#N)CC1CO GIPYSZWEUUHGRI-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002288833 | 2002-10-01 | ||
| JP2002340175 | 2002-11-22 | ||
| JP2003109160 | 2003-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1557414E true PT1557414E (pt) | 2012-04-17 |
Family
ID=32074144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT03748659T PT1557414E (pt) | 2002-10-01 | 2003-10-01 | Compostos de isoquinolina e sua utilização medicinal |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7220759B2 (enExample) |
| EP (1) | EP1557414B1 (enExample) |
| JP (1) | JP4520406B2 (enExample) |
| KR (1) | KR100735781B1 (enExample) |
| CN (1) | CN100390164C (enExample) |
| AT (1) | ATE552252T1 (enExample) |
| CA (1) | CA2500888C (enExample) |
| DK (1) | DK1557414T3 (enExample) |
| ES (1) | ES2380917T3 (enExample) |
| PT (1) | PT1557414E (enExample) |
| TW (1) | TW200424188A (enExample) |
| WO (1) | WO2004031171A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1557414B1 (en) * | 2002-10-01 | 2012-04-04 | Mitsubishi Tanabe Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
| JP4567460B2 (ja) * | 2002-11-22 | 2010-10-20 | 田辺三菱製薬株式会社 | イソキノリン化合物及びその医薬用途 |
| ES2514517T3 (es) | 2007-08-10 | 2014-10-28 | Mitsubishi Tanabe Pharma Corporation | Nueva sal de compuesto de isoquinolina y cristal de la misma |
| TWI499418B (zh) * | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| WO2013004652A1 (de) | 2011-07-04 | 2013-01-10 | Bayer Intellectual Property Gmbh | Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| KR102104144B1 (ko) * | 2012-03-07 | 2020-04-23 | 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 | 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도 |
| WO2015036759A1 (en) * | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| AR098776A1 (es) * | 2013-12-18 | 2016-06-15 | Chiesi Farm Spa | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas |
| AU2020376697B2 (en) * | 2019-10-30 | 2024-03-14 | Digmbio. Inc. | Isoquinolinone derivative, preparation method therefor, and pharmaceutical composition, comprising same as active ingredient, for prevention or treatment of poly(ADP-ribose)polymerase-1 (PARP-1)-associated disease |
| CN113636970B (zh) * | 2021-09-13 | 2023-05-23 | 河北康泰药业有限公司 | 一种异吲哚酮的化合物、制备方法及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1062357A (en) | 1912-05-31 | 1913-05-20 | Warschauer Schrauben Und Drahtfabriken Ag | Nut-lock. |
| US1174272A (en) | 1915-10-27 | 1916-03-07 | Commw Steel | Locomotive-bed. |
| GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| JPS4612454Y1 (enExample) * | 1968-07-26 | 1971-04-30 | ||
| DE2121031A1 (en) | 1971-04-29 | 1972-11-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Base-substd quinazolines - thrombocyte aggregation inhibitors |
| IT1054655B (it) | 1975-08-27 | 1981-11-30 | Lepetit Spa | Derivati condensati del l isochinolina |
| JPS52156875A (en) | 1976-06-23 | 1977-12-27 | Mitsui Toatsu Chem Inc | Preparation of novel isoquinolone derivatives |
| JPS5484597A (en) | 1977-12-15 | 1979-07-05 | Yamanouchi Pharmaceut Co Ltd | Novel heterocyclic compound and its preparation |
| JPS6442472U (enExample) | 1986-06-14 | 1989-03-14 | ||
| US4808595A (en) | 1986-12-24 | 1989-02-28 | Merck & Co., Inc. | Furopyridine sulfonamides and their opthalmological compositions |
| JPS6442472A (en) | 1987-08-10 | 1989-02-14 | Kanebo Ltd | Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient |
| CA1334969C (en) | 1988-08-19 | 1995-03-28 | Mark James Suto | Substituted dihydroisoquinoline and phthalazine derivatives as potentiators of the lethal effects of radiation and certain chemotherapeutic agents, selected compounds, analogs andprocess |
| AU8784698A (en) | 1997-08-15 | 1999-03-08 | Johns Hopkins University, The | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| AU9297998A (en) * | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| AU2004200A (en) | 1999-01-14 | 2000-08-01 | Meiji Seika Kaisha Ltd. | Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives |
| US6677333B1 (en) | 1999-01-26 | 2004-01-13 | Ono Pharmaceutical Co., Ltd. | 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient |
| DE19918211A1 (de) | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JPWO2001079184A1 (ja) | 2000-04-18 | 2004-03-18 | 住友製薬株式会社 | 置換ピペラジン類 |
| WO2002044157A2 (en) | 2000-12-01 | 2002-06-06 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| US6664269B2 (en) | 2001-05-08 | 2003-12-16 | Maybridge Plc | Isoquinolinone derivatives |
| WO2002094790A1 (en) * | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| EP1557414B1 (en) * | 2002-10-01 | 2012-04-04 | Mitsubishi Tanabe Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
| JP4567460B2 (ja) | 2002-11-22 | 2010-10-20 | 田辺三菱製薬株式会社 | イソキノリン化合物及びその医薬用途 |
| JP4612454B2 (ja) | 2005-03-31 | 2011-01-12 | 本田技研工業株式会社 | ブレーキ制御装置 |
-
2003
- 2003-10-01 EP EP03748659A patent/EP1557414B1/en not_active Expired - Lifetime
- 2003-10-01 CN CNB200380100827XA patent/CN100390164C/zh not_active Expired - Fee Related
- 2003-10-01 CA CA2500888A patent/CA2500888C/en not_active Expired - Fee Related
- 2003-10-01 DK DK03748659.4T patent/DK1557414T3/da active
- 2003-10-01 KR KR1020057005596A patent/KR100735781B1/ko not_active Expired - Fee Related
- 2003-10-01 JP JP2005500092A patent/JP4520406B2/ja not_active Expired - Fee Related
- 2003-10-01 PT PT03748659T patent/PT1557414E/pt unknown
- 2003-10-01 AT AT03748659T patent/ATE552252T1/de active
- 2003-10-01 TW TW092127338A patent/TW200424188A/zh not_active IP Right Cessation
- 2003-10-01 WO PCT/JP2003/012608 patent/WO2004031171A1/ja not_active Ceased
- 2003-10-01 ES ES03748659T patent/ES2380917T3/es not_active Expired - Lifetime
-
2004
- 2004-04-30 US US10/836,377 patent/US7220759B2/en not_active Expired - Lifetime
-
2007
- 2007-03-19 US US11/688,103 patent/US7459465B2/en not_active Expired - Lifetime
-
2008
- 2008-11-03 US US12/263,963 patent/US7812178B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE552252T1 (de) | 2012-04-15 |
| WO2004031171A1 (ja) | 2004-04-15 |
| US20090076276A1 (en) | 2009-03-19 |
| CN100390164C (zh) | 2008-05-28 |
| EP1557414A4 (en) | 2007-10-31 |
| TWI338687B (enExample) | 2011-03-11 |
| CA2500888C (en) | 2010-07-13 |
| EP1557414A1 (en) | 2005-07-27 |
| KR20050070024A (ko) | 2005-07-05 |
| US20070161620A1 (en) | 2007-07-12 |
| KR100735781B1 (ko) | 2007-07-06 |
| US7459465B2 (en) | 2008-12-02 |
| US20040248931A1 (en) | 2004-12-09 |
| TW200424188A (en) | 2004-11-16 |
| CA2500888A1 (en) | 2004-04-15 |
| US7812178B2 (en) | 2010-10-12 |
| CN1703410A (zh) | 2005-11-30 |
| US7220759B2 (en) | 2007-05-22 |
| EP1557414B1 (en) | 2012-04-04 |
| ES2380917T3 (es) | 2012-05-21 |
| AU2003268724A1 (en) | 2004-04-23 |
| JPWO2004031171A1 (ja) | 2006-02-02 |
| JP4520406B2 (ja) | 2010-08-04 |
| DK1557414T3 (da) | 2012-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7812178B2 (en) | Isoquinoline compound and pharmaceutical use thereof | |
| US20040176361A1 (en) | Fused heterocyclic compound and medicinal use thereof | |
| CN114008049B (zh) | 用于癌症治疗的egfr抑制剂 | |
| AU2019264253B2 (en) | Factor XIIa inhibitors | |
| TW533211B (en) | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | |
| WO2021051034A1 (en) | Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| ES2732758T3 (es) | Derivados de indano e indolina y su uso como activadores de guanilato-ciclasa soluble | |
| EP1566380B1 (en) | Isoquinoline compounds and medicinal use thereof | |
| CA3150701A1 (en) | Alkynyl quinazoline compounds | |
| JP7208931B2 (ja) | Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 | |
| TW201100385A (en) | Substituted isoquinoline derivative | |
| JP2020143118A (ja) | プロテインキナーゼ阻害剤である新規な２，３，５−置換チオフェン化合物 | |
| WO2015091988A1 (en) | Piperidine compounds having multimodal activity against pain | |
| ES2987269T3 (es) | Inhibidores de MLL1 y agentes anticancerígenos | |
| TWI295290B (en) | Novel pyrrolidine-3,4-dicarboxamide derivatives | |
| TW201033192A (en) | A novel cyanopyrimidine derivative | |
| RU2297411C2 (ru) | Изохинолиновые соединения, промежуточные соединения, способы их получения и применение | |
| CN118434746A (zh) | 一种哒嗪类化合物、其药物组合物及应用 | |
| EP2531487A1 (en) | Aryl benzylamine compounds | |
| CN114751874A (zh) | 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用 | |
| TW202408515A (zh) | 含有kras g12c抑制劑及奧諾拉(aurora)a抑制劑之治療方法 | |
| TW202339706A (zh) | 含醯胺的ｌｏｎｐ１抑制劑化合物、用途及方法 | |
| JP2022506727A (ja) | Ｒｈｏキナーゼ阻害剤、その調製のための方法およびその使用 | |
| HK1081441A1 (zh) | 对钙通道α-2-δ亚基具有亲合力的脯氨酸衍生物 | |
| HK1081441B (zh) | 对钙通道α-2-δ亚基具有亲合力的脯氨酸衍生物 |